"Designing Growth Strategies is in our DNA"

Sickle Cell Disease Treatment Market Size, Share & COVID-19 Impact Analysis, By Treatment Modality [Bone Marrow Transplant, Blood Transfusion, Pharmacotherapy {Hydroxyurea, and Branded Products (Endari, Adakveo, Oxbryta, Zynteglo, PYRUKYND (Mitapivat), CTX001, Inclacumab, MGTA-145, Vamifeport (VIT-2763), ALXN1820, FT-4202, and GBT021601)}], By End-user [Hospitals, Specialty Clinics, and Others], and Regional Forecast, 2023-2030

Last Updated: January 20, 2025 | Format: PDF | Report ID: FBI101009

 


To get information on various segments, share your queries with us

ATTRIBUTE

DETAILS

Study Period

2019-2030

Base Year

2022

Estimated Year

2023

Forecast Period

2023-2030

Historical Period

2019-2021

Growth Rate

CAGR of 20.1% from 2023-2030

Unit

Value (USD Billion)

Segmentation

By Treatment Modality, End-user, and Geography

By Treatment Modality

  • Bone Marrow Transplant
  • Blood Transfusion
  • Pharmacotherapy
    • Hydroxyurea
    • Branded Products
      • Endari
      • Adakveo
      • Oxbryta
      • Zynteglo
      • PYRUKYND (Mitapivat)
      • CTX001
      • Inclacumab
      • MGTA-145
      • Vamifeport (VIT-2763)
      • ALXN1820
      • FT-4202
      • GBT021601

By End-user

 

  • Hospitals
  • Specialty Clinics
  • Others

By Geography

  • U.S. (By Treatment Modality and End-user)
  • Europe (By Treatment Modality, End-user, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Rest of the World (By Treatment Modality, End-user, and Country/Sub-region)
    • India
    • China
    • Japan
    • GCC Countries
    • Rest of ROW

 

  • 2019-2030
  • 2022
  • 2019-2021
  • 103
Multi-report Purchase Plan
    A Customized Plan Will be Created Based on the number of reports you wish to purchase
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X